Prostate cancer is one of the most serious health concerns for men, especially in the UK. It is the second biggest cancer killer among men.
Doctors and researchers have been looking for ways to find this cancer early, before it becomes dangerous. One common method used for this is a blood test called the PSA test.
PSA stands for Prostate-Specific Antigen, a protein made by the prostate gland. High levels of PSA in the blood can be a sign of prostate cancer. But how helpful is this test really? A large new study tried to find the answer.
The study was led by researchers from the universities of Bristol, Oxford, and Cambridge. It included more than 400,000 men between the ages of 50 and 69.
Some of these men were invited to take a single PSA test, while others were not. The researchers then followed these men for 15 years to see if the test had any effect on the number of deaths from prostate cancer.
After 15 years, the results showed that the PSA test only had a small effect. For every 1,000 men who took the test, one fewer man died from prostate cancer compared to those who didn’t take the test. While this might sound like good news, the benefit was very small. And it came with some big problems.
One major problem is called overdiagnosis. This means that the PSA test finds cancers that would never have caused any harm during the person’s lifetime. These cancers grow so slowly that they wouldn’t have become a danger.
But once they are found, many men go through treatments they don’t actually need. These treatments can lead to serious side effects, including infections, problems with controlling the bladder and bowels, and even trouble with sex.
On top of that, being told you have cancer—even if it won’t cause harm—can be very stressful. Many men feel anxiety and fear after getting a cancer diagnosis, even if the cancer isn’t dangerous.
Because of these concerns, Cancer Research UK suggests that people should pay close attention to their bodies. If you notice changes that don’t go away, like problems urinating, you should talk to a doctor. These symptoms are often caused by non-cancer issues, but it’s still worth getting checked.
Right now, the UK does not have a national screening program for prostate cancer. That’s because the PSA test isn’t very good at telling the difference between dangerous and harmless cancers. This can lead to both overdiagnosis and underdiagnosis, which means missing aggressive cancers that need quick treatment.
However, scientists are working hard to find better ways to detect prostate cancer early. New tools, like MRI scans before doing a biopsy, are helping doctors make better decisions. Researchers are also trying to develop new tests that can tell which cancers are truly dangerous.
Cancer Research UK is leading the way in funding these studies. They are also working on better treatments for men who already have advanced prostate cancer. One of their biggest efforts is the STAMPEDE trial, which looks at ways to help men with prostate cancer live longer.
In the end, deciding whether to get a PSA test is a personal choice. Men should stay informed, pay attention to any changes in their health, and have honest talks with their doctors. The goal is to catch dangerous cancers early without causing harm from unnecessary tests or treatments.
If you care about prostate cancer, you might also want to read about five types of bacteria linked to aggressive prostate cancer and a new strategy to treat advanced prostate cancer. Other recent studies show a new way to reduce the spread of prostate cancer and how a combination of three drugs can help men with advanced cancer live longer.
If you care about prostate cancer, please read studies about a natural ally against prostate cancer, and supplements and keto diet can boost immunotherapy for prostate cancer.
For more health information, please see recent studies about how to harness the power of anti-cancer foods and supplements, and low-fat diet may help stop cancer growth.
The full study results can be found in the journal JAMA.
Copyright © 2025 Knowridge Science Report. All rights reserved.
